(PharmaNewsWire.Com, June 17, 2017 ) Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body. Report Highlights
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 4, 11 and 3 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Central Nervous System, Hematological Disorders, Respiratory, Cardiovascular and Ophthalmology which include indications Rheumatoid Arthritis, Ulcerative Colitis, Atopic Dermatitis, Alopecia, Psoriasis, Chronic Lymphocytic Leukemia (CLL) , Diffuse Large B-Cell Lymphoma, Psoriatic Arthritis, Vitiligo, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Ankylosing Spondylitis (Bekhterev's Disease) , B-Cell Non-Hodgkin Lymphoma, Crohn's Disease (Regional Enteritis) , Graft Versus Host Disease (GVHD) , Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) , Mantle Cell Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL) , Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia, Anaplastic Large Cell Lymphoma (ALCL) , Asthma, Auto Inflammatory Disease, Autoimmune Disorders, Breast Cancer, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Endometrial Cancer, Eosinophilia, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Giant Cell Arteritis, Hairy Cell Leukemia, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Laryngeal Cancer, Lupus Erythematosus, Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease) , Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris) , Post-Polycythemia Vera Myelofibrosis (PPV-MF) , Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL) , Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Respiratory Tract Inflammatory Disorders, Sicca Syndrome (Sjogren) , Skin Inflammation, Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) , Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma) .
Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
AbbVie Inc Aclaris Therapeutics Inc Advinus Therapeutics Ltd Astellas Pharma Inc AstraZeneca Plc Chipscreen Biosciences Ltd CJ HealthCare Corp Eli Lilly and Company Galapagos NV Incyte Corp Japan Tobacco Inc Jiangsu Hengrui Medicine Co Ltd Nissan Chemical Industries Ltd Pfizer Inc Portola Pharmaceuticals Inc Sareum Holdings Plc Theravance Biopharma Inc Vectura Group Plc
Number of Products under Development by Stage of Development, H1 2017 10 Number of Products under Development by Therapy Areas, H1 2017 11 Number of Products under Development by Indications, H1 2017 12 Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017 14 Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017 15 Number of Products under Development by Indications, H1 2017 (Contd..3) , H1 2017 16 Number of Products under Development by Companies, H1 2017 17 Products under Development by Companies, H1 2017 18 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 19 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 20 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 21 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 22 Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 23 Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 24 Number of Products by Stage and Mechanism of Actions, H1 2017 25 Number of Products by Stage and Route of Administration, H1 2017 27 Number of Products by Stage and Molecule Type, H1 2017 28 Pipeline by AbbVie Inc, H1 2017 29 Pipeline by Aclaris Therapeutics Inc, H1 2017 30 Pipeline by Advinus Therapeutics Ltd, H1 2017 30 Pipeline by Astellas Pharma Inc, H1 2017 31 Pipeline by AstraZeneca Plc, H1 2017 31 Pipeline by Chipscreen Biosciences Ltd, H1 2017 32 Pipeline by CJ HealthCare Corp, H1 2017 32 Pipeline by Eli Lilly and Company, H1 2017 33 Pipeline by Galapagos NV, H1 2017 34 Pipeline by Incyte Corp, H1 2017 35 Pipeline by Japan Tobacco Inc, H1 2017 37 Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 37 Pipeline by Nissan Chemical Industries Ltd, H1 2017 38 Pipeline by Pfizer Inc, H1 2017 38 Pipeline by Portola Pharmaceuticals Inc, H1 2017 39 Pipeline by Sareum Holdings Plc, H1 2017 40 Pipeline by Theravance Biopharma Inc, H1 2017 41 Pipeline by Vectura Group Plc, H1 2017 41 Dormant Projects, H1 2017 120 Discontinued Products, H1 2017 121 Discontinued Products, H1 2017 (Contd..1) , H1 2017 122
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
